Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

PURPOSE: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1) improves the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebbé, Celeste, Meyer, Nicolas, Mortier, Laurent, Marquez-Rodas, Ivan, Robert, Caroline, Rutkowski, Piotr, Menzies, Alexander M., Eigentler, Thomas, Ascierto, Paolo A., Smylie, Michael, Schadendorf, Dirk, Ajaz, Mazhar, Svane, Inge Marie, Gonzalez, Rene, Rollin, Linda, Lord-Bessen, Jennifer, Saci, Abdel, Grigoryeva, Elena, Pigozzo, Jacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455714/
https://www.ncbi.nlm.nih.gov/pubmed/30811280
http://dx.doi.org/10.1200/JCO.18.01998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455714/
https://www.ncbi.nlm.nih.gov/pubmed/30811280
http://dx.doi.org/10.1200/JCO.18.01998

Ejemplares similares